Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea

Table 2

Clinical and laboratory values associated with survival on univariate analysis.

Characteristic	ORR ≥ PR (%)	𝑃	5-year PFS (%)	𝑃	5-year OS (%)	𝑃
Age, years
<65	66.7	0.327	64.8	0.708	82.2	0.024
≥65	55.3		37.0		36.8
Gender
Male	64.4	0.197	46.8	0.530	65.9	0.130
Female	41.7		77.9		45.0
BM lymphocyte, %
<50	63.0	0.461	61.8	0.478	40.6	0.610
≥50	52.9		26.2		52.5
Cytogenetic abnormalities
Presence	75.0	0.466	64.3	0.599	50.0	0.444
Absence	58.7		50.9		42.4
Hemoglobin, g/dL
<11.5	61.3	0.732	54.3	0.140	60.2	0.700
≥11.5	55.6		0.0		87.5
Platelet count, ×10^9/L
<100	69.2	0.479	0.0	0.049	61.9	0.124
≥100	58.6		60.6		63.0
ALC, ×10^9/L
<1.0	20.0	0.069	33.3	0.611	40.0	0.224
≥1.0	64.6		54.3		64.6
CRP, mg/dL
<5	58.0	0.817	46.4	0.937	65.5	0.096
≥5	61.5		51.3		48.6
Serum 𝛽2-microglobulin, mg/L
<3	66.7	0.862	48.9	0.130	50.0	0.143
≥3	64.0		50.6		58.4
Serum albumin, g/dL
<3.5	58.5	0.683	43.1	0.712	44.8	0.010
≥3.5	63.3		64.4		84.1
LDH, IU/L
<450	59.7	0.688	50.1	0.849	61.8	0.403
≥450	66.7		65.6		72.9
B symptom
Presence	87.5	0.132	83.3	0.666	60.0	0.385
Absence	56.5		48.8		62.8
ECOG, (%)
0-1	67.4	0.057	68.7	0.012	72.6	0.004
≥2	43.5		18.1		26.9
Hyperviscosity syndrome
Presence	25.0	0.055	58.3	0.980	0.0	0.918
Absence	63.8		49.7		66.2
Splenomegaly
Presence	61.1	0.838	77.4	0.342	0.0	0.300
Absence	58.3		49.5		52.7
Hepatomegaly
Presence	57.1	0.884	40.0	0.246	28.6	0.913
Absence	60.0		42.5		45.1
ISSWM (%)
Low	57.1	0.567	66.7	0.912	50.0	0.380
Intermediate	58.8		58.7		58.0
High	75.0		0.0		58.4
ISS (%)
I	61.5	0.522	48.7	0.714	85.7	0.004
II	69.2		41.9		84.8
III	53.8		64.7		36.8
Treatment regimen
Novel agent combined chemotherapy	92.9	0.006	79.1	0.418	100.0	0.067
Conventional chemotherapy	52.6		46.3		53.0

ORR: overall response rates; PR: partial response rates; 5-year PFS: 5-year progression-free survival rates; 5-year OS: 5-year overall survival rates; BM: bone marrow; ALC: absolute lymphocyte count; CRP: C-reactive protein; LDH: lactate dehydrogenase; ECOG: Eastern Cooperative Oncology Group performance status; ISSWM: International Prognostic Scoring System for Waldenstrom’s Macroglobulinemia; ISS: international staging system.